CLINICAL_TRIALS
trial_result
· 2019-03-21
Clinical Trial Update: Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation [Phase 2]
Summary
Phase 2 trial investigating regorafenib in gastrointestinal stromal tumor (GIST) with a secondary C-KIT exon 17 mutation has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chang Gung Memorial Hospital | Conditions: Gastrointestinal Stromal Tumour (GIST) | Phase 2 | Status: COMPLETED